Brown JR et al. Pooled analysis of cardiovascular events from clinical trials evaluating acalabrutinib monotherapy in patients with chronic lymphocytic leukemia (CLL). ASH 2020;Abstract 3146.
Alsina M et al. Updated results from the phase I CRB-402 study of anti-BCMA CAR-T cell therapy bb21217 in patients with relapsed and refractory multiple myeloma: Correlation of expansion and duration of response with T cell phenotypes. ASH 2020;Abstract 130.
Berdeja J et al. Efficacy and safety of idecabtagene vicleucel (ide-cel, bb2121) in elderly patients with relapsed and refractory multiple myeloma: KarMMa subgroup analysis. ASH 2020;Abstract 1367.
Chari A et al. A phase 1, first-in-human study of talquetamab, a G protein-coupled receptor family c group 5 member D (GPRC5D) x CD3 bispecific antibody, in patients with relapsed and/or refractory multiple myeloma (RRMM). ASH 2020;Abstract 290.
Chen CI et al. Selinexor in combination with pomalidomide and dexamethasone (SPd) for treatment of patients with relapsed refractory multiple myeloma (RRMM). ASH 2020;Abstract 726.
Cohen AD et al. Initial clinical activity and safety of BFCR4350A, a FcRH5/CD3 T-cell-engaging bispecific antibody, in relapsed/refractory multiple myeloma. ASH 2020;Abstract 292.
Costa LJ et al. Assessment of minimal residual disease by next-generation sequencing and fluorodeoxyglucose-positron emission tomography in patients with relapsed/refractory multiple myeloma treated with venetoclax in combination with carfilzomib and dexamethasone. ASH 2020;Abstract 2251.
Dimopoulos MA et al. Apollo: Phase 3 randomized study of subcutaneous daratumumab plus pomalidomide and dexamethasone (D-Pd) versus pomalidomide and dexamethasone (Pd) alone in patients (pts) with relapsed/refractory multiple myeloma (RRMM). ASH 2020;Abstract 412.
Facon T et al. The phase 3 TOURMALINE-MM2 trial: Oral ixazomib, lenalidomide, and dexamethasone (IRd) vs placebo-rd for transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM). ASH 2020;Abstract 551.
Garfall AL et al. Updated phase 1 results of teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in relapsed and/or refractory multiple myeloma (RRMM). ASH 2020;Abstract 180.
Kaufman JL et al. Daratumumab (DARA) plus lenalidomide, bortezomib, and dexamethasone (RVd) in patients with transplant-eligible newly diagnosed multiple myeloma (NDMM): Updated analysis of Griffin after 12 months of maintenance therapy. ASH 2020;Abstract 549.
Kazandjian D et al. Treatment of high risk (HR) smoldering multiple myeloma (SMM) with carfilzomib, lenalidomide, and dexamethasone (KRd) followed by lenalidomide maintenance (-R): A phase 2 clinical and correlative study. ASH 2020;Abstract 548.
Lin Y et al. Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T cell therapy, in patients with relapsed and refractory multiple myeloma: Updated results from phase 1 CRB-401 study. ASH 2020;Abstract 131.
Lonial S et al. DREAMM-2: Single-agent belantamab mafodotin (belamaf) in patients with relapsed/refractory multiple myeloma (RRMM) — 1-year outcomes by prior therapies. ASH 2020;Abstract 1417.
Lonial S et al. Recovery of ocular events with longer-term follow-up in the DREAMMM-2 study of single-agent belantamab mafodotin (belamaf) in patients with relapsed or refractory multiple myeloma (RRMM). ASH 2020;Abstract 3224.
Madduri D et al. CARTITUDE-1: Phase 1b/2 study of ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T cell therapy, in relapsed/refractory multiple myeloma. ASH 2020;Abstract 177.
Martin T et al. Depth of response and response kinetics of isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma: Ikema interim analysis. ASH 2020;Abstract 414.
Ocio E et al. ANCHOR (OP-104): Melflufen plus dexamethasone (dex) and daratumumab (dara) or bortezomib (BTZ) in relapsed/refractory multiple myeloma (RRMM) refractory to an IMiD and/or a proteasome inhibitor (PI) — Updated efficacy and safety. ASH 2020;Abstract 417.
Perrot A et al. Early versus late autologous stem cell transplant in newly diagnosed multiple myeloma: Long-term follow-up analysis of the IFM 2009 trial. ASH 2020;Abstract 143.
Popat R et al. DREAMM-6: Safety, tolerability and clinical activity of belantamab mafodotin (belamaf) in combination with bortezomib/dexamethasone (BorDex) in relapsed/refractory multiple myeloma (RRMM). ASH 2020;Abstract 1419.
Raab MS et al. Safety and preliminary efficacy results from a phase II study evaluating combined BRAF and MEK inhibition in relapsed/refractory multiple myeloma (rrMM) patients with activating BRAF V600E mutations: The GMMG-Birma trial. ASH 2020;Abstract 294.
Van De Donk NWCJ et al. First results of iberdomide (IBER; CC-220) in combination with dexamethasone (DEX) and daratumumab (DARA) or bortezomib (BORT) in patients with relapsed/refractory multiple myeloma (RRMM). ASH 2020;Abstract 724.